What Indomo does

Indomo (doing business as ACOM Labs, Inc., a Delaware-incorporated corporation headquartered in Boston with a San Francisco mailing address) is a clinical-stage therapeutics company developing a drug-device combination platform for at-home treatment of inflammatory acne lesions. The company's core offering, the ClearPen™ System, pairs a novel intradermal self-injection device (ClearPen) with a corticosteroid drug candidate (DT-001, based on triamcinolone acetonide) to enable patients to self-administer intralesional injections at home, replicating a procedure that has been the in-office dermatology standard of care for 50+ years and is recommended by the American Academy of Dermatology.

The underlying technology combines a patented intradermal self-injection mechanism designed to control dosage, depth, and volume with a reformulated corticosteroid drug candidate. Indomo has completed two investigator-led trials and a sponsored n=56 trial demonstrating equivalence between patient self-injection and provider injection with zero adverse events and significant lesion improvement reported by over two-thirds of participants within 24 hours. Phase 2 clinical trials are planned for 2026, with DT-001 manufacturing contracted to Lifecore Biomedical under a development services agreement signed in March 2026.

The company is pre-revenue with no commercial products, no FDA approval, and no disclosed pricing. Its go-to-market motion is product-led, targeting the underserved patient population of 50 million Americans affected by acne who lack access to dermatologists or prefer at-home treatment. Indomo maintains a clinical trial waitlist as its primary mid-funnel conversion mechanism, and the planned commercial model appears to be direct-to-consumer distribution of the combined device-plus-drug system. The company raised $25 million in late 2025 led by Atomic, Foresite Capital, and Polaris Partners to fund clinical development and platform expansion.

Name

Indomo

Legal name

ACOM Labs, Inc.

Website

https://indomotx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Indomo is a clinical-stage therapeutics company developing the ClearPen System, a drug-device combination of an intradermal self-injection device and DT-001 corticosteroid, enabling at-home self-administered treatment of inflammatory acne lesions for the 50 million Americans affected by acne.

Ownership category

akta.pro rank

Product category

Dermatology Therapeutics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Pharmaceutical Preparation Manufacturing (325412)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Pharmaceutical Preparations (2834)

akta.pro primary industry

Auto-Injectors (Disposable & Reusable) (HLAHAIAB)

Keywords

• Drug-device combination
• Intradermal injection
• Acne therapeutics
• Self-injection devices
• Dermatology treatments

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. ClearPen System (DT-001 + Device): Clinical-stage company developing a drug-device combination product. The ClearPen system combines DT-001 corticosteroid with a self-injection device for at-home acne treatment. Revenue model not yet disclosed as products are under development and have not been evaluated by FDA or any regulatory authority.

Go-to-market motion2 records

Marketing channels4 records

Core offering

Indomo is developing the ClearPen™ System, a drug-device combination platform that pairs the DT-001 corticosteroid (triamcinolone acetonide) drug candidate with a novel intradermal self-injection device. The system is designed to enable patients to self-administer intralesional acne injections at home, replicating the in-office standard of care for moderate to severe inflammatory acne lesions. Indomo's products are currently under development and have not been evaluated by the FDA or any regulatory health authority.

Product overview

Indomo is a clinical-stage therapeutics company developing a drug-device combination platform for at-home dermatological treatments. The company's primary offering consists of the ClearPen™ intradermal self-injection device combined with DT-001, a corticosteroid drug candidate. Together, this device-plus-drug platform enables patients to self-administer intralesional injections for inflammatory acne lesions at home, shifting the in-office standard of care (intralesional triamcinolone acetonide injections) into a home setting. The ClearPen controls dosage, depth, and volume of injection, and the company is advancing toward Phase 2 clinical trials in 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• ClearPen™ System The ClearPen™ System is a drug-device combination product combining the DT-001 corticosteroid (triamcinolone acetonide) drug candidate with a novel intradermal self-injection device designed to enable patients to self-administer intralesional acne injections at home for the treatment of moderate to severe inflammatory acne lesions. The device controls dosage, depth, and volume of injection to replicate the in-office standard of care.

Quantifiable outcome

• Over two-thirds of participants reported significant improvement of lesion within 24 hours
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Lifecore BiomedicalcoreStrategic or Co-development Partner · 4 March 2026Lifecore Biomedical has entered into a development services agreement with Indomo to manufacture engineering and clinical batches of DT-001 drug candidate for planned Phase 2 clinical trials in 2026. This is the second agreement between the companies, with Lifecore having previously provided formulation and process optimization services for the DT-001 program. The agreement supports Lifecore's expansion beyond ophthalmic therapies into autoinjector technologies while Indomo develops DT-001 for use with its ClearPen self-injection device.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Unilife Corporation: Developer of injectable drug-delivery devices including auto-injectors and intradermal delivery systems. Directly comparable to ClearPen's drug-device architecture, and another of CEO Rick Bente's former companies.
• Insulet Corporation: Maker of the Omnipod tubeless insulin pump — a wearable drug-delivery device for patient self-administration at home. Directly comparable to Indomo's ClearPen as a patient-facing injectable/wearable drug-device combination, and notably CEO Rick Bente's former company.
• Curology: Tele-dermatology platform providing custom prescription acne and skincare treatments shipped directly to consumers. Comparable as a direct-to-consumer acne-treatment competitor pursuing the at-home convenience thesis.
• Hims & Hers Health: Direct-to-consumer tele-health platform offering prescription dermatology treatments including for acne. Comparable as a consumer-facing acne/dermatology brand with at-home delivery, and was co-founded by Indomo's Chairman Jack Abraham — providing a direct strategic and operational template.
• Starface: Consumer acne-care brand selling patches and skincare direct to consumers; Indomo's COO Cara Davis was part of Starface's founding team. Comparable as a consumer-first acne brand with overlapping end-customer base.
• Apostrophe (tele-dermatology): Tele-dermatology platform offering custom prescription acne and rosacea treatments prescribed online and delivered to patients. Comparable as a consumer-facing prescription dermatology platform with overlapping patient acquisition motion.

Broad incumbents

• Galderma: Global dermatology-focused pharmaceutical company with leading prescription acne franchises (Epiduo, Differin, etc.). Comparable as the incumbent leader in prescription acne therapeutics that Indomo's intralesional platform would compete with or partner alongside.
• Bausch Health (Ortho Dermatologics): Dermatology division of Bausch Health with established prescription acne portfolio (Onexton, Retin-A Micro, etc.). Comparable as a broad incumbent dermatology player whose portfolio overlaps with Indomo's inflammatory acne indication.
• West Pharmaceutical Services: Major supplier of elastomeric components, containment systems, and drug-delivery device platforms for injectable therapeutics. Comparable as a broad incumbent in the injectable drug-delivery infrastructure layer that Indomo's ClearPen competes against or partners with.
• AbbVie (Allergan Aesthetics): Pharmaceutical incumbent with a major aesthetics and dermatology franchise (including former Allergan assets). Comparable as a broad incumbent whose aesthetics/dermatology portfolio overlaps with Indomo's intralesional corticosteroid positioning, and notably connected via board observer Brent Saunders (former Allergan CEO).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/indomotx

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indomo